Chemerin Novel Biomarker As a Prognostic Factor for Cardiovascular Complications in Type 2 Diabetic Patients

Document Type : Original Article

Authors

1 Hormones Department, National Research Center, Giza (Egypt)

2 Biochemistry Departments, Faculty of Science, Helwan University, Cairo (Egypt)

3 Biochemistry Department, National Institute of Diabetes andEndocrinology, Cairo (Egypt).

10.12816/0033757

Abstract

Objective:the present study was aimed to assess chemerin as prognostic factor forcardiovascular complications in type2 diabetic patients.
Patients and methods:forty type 2 diabetic patients without cardiovascular disease, forty type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in thepresent study.Chemerinlevels were assayed and correlated with clinical pathological parameters.ROC curve analysis was also done for this biochemical marker.
Results:the mean level of chemerinwas 57.65± 15.69 ng/l in diabetic subjects versus 93.97 ± 26.62 ng/l for the cardio-diabetic subjects (P < 0.0001).The chemerin levels were significantly elevated in the cardio-diabetic patients with increasing-reactive protein(CRP), triglycerides(TG), fasting blood glucose (FBG),  glycated hemoglbin(HbA1C), micro-albumin and cholesterol (P < 0.0001, P < 0.0001, P = 0.005, P=0.04, P=0.011andP=0.0001 respectively). From the ROC curve analysis, it was observed that the area under curve for chemerin was 0.877. This finding indicates the good validity of the above biomarker as aprognostic factor for cardiovascular complication in type 2 diabetic patients.
Conclusion:it could be concluded that chemerin can be used as prognostic biomarker for cardiovascular complications in type 2 diabetic patients.
 

Keywords

The Egyptian Journal of Hospital Medicine
Volume 65, Issue 1
October 2016
Pages 491-497

Files

Share

How to cite

Statistics